» Articles » PMID: 19648928

Aberrant Luminal Progenitors As the Candidate Target Population for Basal Tumor Development in BRCA1 Mutation Carriers

Abstract

Basal-like breast cancers arising in women carrying mutations in the BRCA1 gene, encoding the tumor suppressor protein BRCA1, are thought to develop from the mammary stem cell. To explore early cellular changes that occur in BRCA1 mutation carriers, we have prospectively isolated distinct epithelial subpopulations from normal mammary tissue and preneoplastic specimens from individuals heterozygous for a BRCA1 mutation. We describe three epithelial subsets including basal stem/progenitor, luminal progenitor and mature luminal cells. Unexpectedly, we found that breast tissue from BRCA1 mutation carriers harbors an expanded luminal progenitor population that shows factor-independent growth in vitro. Moreover, gene expression profiling revealed that breast tissue heterozygous for a BRCA1 mutation and basal breast tumors were more similar to normal luminal progenitor cells than any other subset, including the stem cell-enriched population. The c-KIT tyrosine kinase receptor (encoded by KIT) emerged as a key marker of luminal progenitor cells and was more highly expressed in BRCA1-associated preneoplastic tissue and tumors. Our findings suggest that an aberrant luminal progenitor population is a target for transformation in BRCA1-associated basal tumors .

Citing Articles

Noncanonical Wnt/Ror2 Signaling Regulates Basal Cell Fidelity and Branching Morphogenesis in the Mammary Gland.

Si H, Mendoza Mendoza E, Esquivel M, Creighton C, Xu J, Roarty K bioRxiv. 2025; .

PMID: 40060578 PMC: 11888327. DOI: 10.1101/2025.02.25.640099.


Deciphering Precursor Cell Dynamics in Esophageal Preneoplasia via Genetic Barcoding and Single-Cell Transcriptomics.

Jang J, Ko K, Zhang J, Jun S, Park J bioRxiv. 2025; .

PMID: 40060545 PMC: 11888434. DOI: 10.1101/2025.02.26.637920.


Mammalian Species-Specific Resistance to Mammary Cancer.

Barash I J Mammary Gland Biol Neoplasia. 2025; 30(1):3.

PMID: 40048007 PMC: 11885404. DOI: 10.1007/s10911-025-09578-4.


Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.

Moser S, Jonkers J Cancer Discov. 2025; 15(3):461-480.

PMID: 40025950 PMC: 11893084. DOI: 10.1158/2159-8290.CD-24-1326.


Mechanism of action of genistein on breast cancer and differential effects of different age stages.

Xiang Z, Ma B, Pei X, Wang W, Gong W Pharm Biol. 2025; 63(1):141-155.

PMID: 39996512 PMC: 11864014. DOI: 10.1080/13880209.2025.2469607.


References
1.
Xu X, Wagner K, Larson D, Weaver Z, Li C, Ried T . Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 1999; 22(1):37-43. DOI: 10.1038/8743. View

2.
Kauff N, Domchek S, Friebel T, Robson M, Lee J, Garber J . Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008; 26(8):1331-7. PMC: 3306809. DOI: 10.1200/JCO.2007.13.9626. View

3.
Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D . Purification and unique properties of mammary epithelial stem cells. Nature. 2006; 439(7079):993-7. DOI: 10.1038/nature04496. View

4.
Nielsen T, Hsu F, Jensen K, Cheang M, Karaca G, Hu Z . Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10(16):5367-74. DOI: 10.1158/1078-0432.CCR-04-0220. View

5.
Wagner K, Wall R, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L . Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res. 1997; 25(21):4323-30. PMC: 147032. DOI: 10.1093/nar/25.21.4323. View